AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29632615 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 961
Study 29632674 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 60
Study 29632674 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 60
Study 29632720 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade (knockout or antibody blockade)
Number of subjects: 0
Study 29632720 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 overexpression and exposure to recombinant PD-L1
Number of subjects: 0
Study 29632720 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 0
Study 29632720 — intervention group
Group type: COMPARATOR
Intervention: Palliative radiotherapy and pembrolizumab
Number of subjects: 0
Study 29632896 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative and community relevant interventions for improving women's access to PHC services
Number of subjects: 0
Study 29632896 — intervention group
Group type: COMPARATOR
Intervention: Control sites (PHCs in six communities of similar status)
Number of subjects: 0
Study 29632895 — intervention group
Group type: EXPERIMENTAL
Intervention: Warrior Wellness exercise intervention (12-week supervised, facility-based exercise intervention, 3 sessions per week of multi-component exercise training targeting strength, endurance, balance, and flexibility)
Number of subjects: 0
Study 29632895 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 29632996 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved ARDS
Number of subjects: 2377
Study 29632996 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed ARDS
Number of subjects: 2377
Study 29632996 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed severe ARDS
Number of subjects: 2377
Study 29632996 — intervention group
Group type: COMPARATOR
Intervention: Higher tidal volume on day 1 of ARDS
Number of subjects: 2377
Study 29632996 — intervention group
Group type: COMPARATOR
Intervention: Age, non-respiratory SOFA score, lower PEEP and P/F ratio, higher peak pressure and respiratory rate
Number of subjects: 2377
Study 29632996 — intervention group
Group type: COMPARATOR
Intervention: pH and presence of immunosuppression or neoplasm
Number of subjects: 2377
Study 29632996 — intervention group
Group type: COMPARATOR
Intervention: Day 2 ARDS reclassification
Number of subjects: 2377
Study 29633228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 252
Study 29633228 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 252
Study 29633605 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+ cells
Number of subjects: 77
Study 29633605 — intervention group
Group type: EXPERIMENTAL
Intervention: MNCs
Number of subjects: 77
Study 29633605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 29633714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) in primary somatosensory cortex (S1)
Number of subjects: 1
Study 29633714 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of electrodes with multimodal properties
Number of subjects: 1
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist visits (1-2 visits in the previous year)
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner visits (4 or more visits in the previous year)
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietician visits
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and mental quality of life (QoL)
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of end-stage renal disease within 5 years
Number of subjects: 3033
Study 29635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk profile comparison between genders
Number of subjects: 3033
Study 29635379 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice a day
Number of subjects: 527
Study 29635379 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 527
Study 29635379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 29635415 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (preexposure prophylaxis) offered to participants; specific dosage and duration not mentioned.
Number of subjects: 0
Study 29635415 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence interventions suggested; specific details not mentioned.
Number of subjects: 0
Study 29635495 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Body Weight Planner (NIH BWP)
Number of subjects: 0
Study 29635495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pennington Biomedical Research Center Weight Loss Predictor (PBRC WLP)
Number of subjects: 0
Study 29635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration <6 months
Number of subjects: 5905
Study 29635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI ≥30 kg/m2
Number of subjects: 5905
Study 29635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants weighing <2.5 kg at birth
Number of subjects: 5905
Study 29635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants weighing ≥4 kg at birth
Number of subjects: 5905
Study 29635498 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of total glucosinolate intake
Number of subjects: 200907
Study 29635498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 major glucosinolate subtypes
Number of subjects: 200907
Study 29635498 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cruciferous vegetable consumption
Number of subjects: 200907
Study 29635500 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight obesity (NWO)
Number of subjects: 178
Study 29635500 — intervention group
Group type: COMPARATOR
Intervention: Nonobese
Number of subjects: 178
Study 29635500 — intervention group
Group type: EXPERIMENTAL
Intervention: Preobese-obese
Number of subjects: 178
Study 29635504 — intervention group
Group type: EXPERIMENTAL
Intervention: NuVal shelf nutrition labels
Number of subjects: 0
Study 29635527 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 33
Study 29635629 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin
Number of subjects: 762
Study 29635629 — intervention group
Group type: COMPARATOR
Intervention: Disc diffusion and Etest
Number of subjects: 762
Study 29635629 — intervention group
Group type: COMPARATOR
Intervention: Vitek 2
Number of subjects: 762
Study 29635629 — intervention group
Group type: COMPARATOR
Intervention: Routine methods for susceptibility testing
Number of subjects: 762
Study 29635876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy at a maintenance dose of 1.0 g/kg every 3 weeks for 52 weeks.
Number of subjects: 13
Study 29636030 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage surgical strategy (debridement-negative pressure therapy and flap coverage) with prolonged antimicrobial therapy
Number of subjects: 61
Study 29636042 — intervention group
Group type: EXPERIMENTAL
Intervention: Location where the questionnaire was completed (at home or at the general practice)
Number of subjects: 1102
Study 29636042 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of insulin, having some problems with T2D self-care, coffee consumption
Number of subjects: 1102
Study 29636042 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1102
Study 29636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest sex-specific quartile of pectoralis muscle area (PMA)
Number of subjects: 3705
Study 29636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis muscle area (PMA)
Number of subjects: 3705
Study 29636050 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral erector spinae muscle area (PVMA)
Number of subjects: 3705
Study 29636274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) + Belimumab (BLM)
Number of subjects: 16
Study 29636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior intervention with smartphone-based self-monitoring
Number of subjects: 26
Study 29636320 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior intervention with paper diary-based self-monitoring
Number of subjects: 26
Study 29636320 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 26
Study 29636319 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging alone
Number of subjects: 512
Study 29636319 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging plus phone coaching
Number of subjects: 512
Study 29636319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 512
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 2
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: WSESSSS score ≥ 8
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 3
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score ≥ 14
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-3 septic-shock definition combined with WSESSSS ≥ 8
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: CPIRO score ≥ 3
Number of subjects: 93
Study 29636790 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 4 and WSESSSS ≥ 8 with or without septic-shock
Number of subjects: 93
Study 29636983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening and core stabilization program (10 sessions, twice a week for 6 weeks)
Number of subjects: 20
Study 29636983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening and core stabilization program
Number of subjects: 20
Study 29636984 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily protein supplement (120 mmol of solutes, allowing an extra 163 mL free water loss) for 4 weeks
Number of subjects: 40
Study 29636984 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily protein supplement
Number of subjects: 40
Study 29637088 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 978
Study 29637088 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (minimum 12 hours) followed by oral antibiotics (total course 10 days)
Number of subjects: 978
Study 29637195 — intervention group
Group type: EXPERIMENTAL
Intervention: SEID-positive group (n=45)
Number of subjects: 120
Study 29637195 — intervention group
Group type: COMPARATOR
Intervention: SEID-negative group (n=69)
Number of subjects: 120
Study 29637195 — intervention group
Group type: EXPERIMENTAL
Intervention: SEID-positive and SEID-negative groups
Number of subjects: 120
Study 29637198 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling using a low-cost servo-controlled device (set core temperature 33.5°C) for 72 hours, followed by passive rewarming.
Number of subjects: 82
Study 29637198 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling using a low-cost servo-controlled device.
Number of subjects: 82
Study 29637481 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29638161 — intervention group
Group type: EXPERIMENTAL
Intervention: High Insulin Studies (HISs)
Number of subjects: 11
Study 29638161 — intervention group
Group type: COMPARATOR
Intervention: Low Insulin Studies (LISs)
Number of subjects: 11
Study 29638206 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-IFN response gene scoring system using NanoString technology
Number of subjects: 0
Study 29638206 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-IFN response gene scoring system
Number of subjects: 0
Study 29641297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg on a 2/1 schedule
Number of subjects: 60
Study 29641374 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication monitoring sensors
Number of subjects: 0
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to poor metabolizers (PMs)
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to intermediate metabolizers (IMs)
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to patients without a nonfunctional allele
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to non-ACS patients
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to ACS patients
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to PMs at 6 months
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to IMs at 6 months
Number of subjects: 931
Study 29642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to patients without a nonfunctional allele at 6 months
Number of subjects: 931
Study 29642921 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based perturbed-balance training (30 sessions on an instrumented treadmill with BAR-TM delivering random pushes)
Number of subjects: 2
Study 29642921 — intervention group
Group type: COMPARATOR
Intervention: Control participant (no specific intervention mentioned)
Number of subjects: 2
Study 29643053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention with daily questionnaires
Number of subjects: 190
Study 29643053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention
Number of subjects: 190
Study 29643053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile app)
Number of subjects: 190
Study 29643063 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib, a Checkpoint Kinase 1 Inhibitor
Number of subjects: 0
Study 29643170 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care surgical approach for iSGS
Number of subjects: 0
Study 29643258 — intervention group
Group type: EXPERIMENTAL
Intervention: VASCOG criteria for diagnosis of mild and major NCD
Number of subjects: 404
Study 29643258 — intervention group
Group type: COMPARATOR
Intervention: Standardized battery from the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network
Number of subjects: 404
Study 29643830 — intervention group
Group type: EXPERIMENTAL
Intervention: StrokeVision app-based assessment
Number of subjects: 48
Study 29643830 — intervention group
Group type: COMPARATOR
Intervention: Traditional bedside testing
Number of subjects: 48
Study 29643830 — intervention group
Group type: COMPARATOR
Intervention: Conventional bedside testing
Number of subjects: 48
Study 29643830 — intervention group
Group type: COMPARATOR
Intervention: Gold standard testing
Number of subjects: 48
Study 29643830 — intervention group
Group type: COMPARATOR
Intervention: Usual screening practice
Number of subjects: 48
Study 29643830 — intervention group
Group type: EXPERIMENTAL
Intervention: StrokeVision digital assessment
Number of subjects: 48
Study 29643928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet (LED) for eight weeks
Number of subjects: 85
Study 29643928 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 85
Study 29645077 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for predicting colorectal cancer (CRC) based on clinical characteristics including rectal bleeding, weight loss, and changes in bowel habits.
Number of subjects: 362
Study 29645077 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for predicting CRC.
Number of subjects: 362
Study 29645077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal bleeding with weight loss and changes in bowel habits.
Number of subjects: 362
Study 29649002 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib treatment
Number of subjects: 18
Study 29649027 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU opioid exposure
Number of subjects: 295
Study 29649027 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain symptoms
Number of subjects: 295
Study 29649027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity score
Number of subjects: 295
Study 29649027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference with daily life
Number of subjects: 295
Study 29649027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain interference score
Number of subjects: 295
Study 29649055 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 212
Study 29649055 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 212
Study 29649137 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29649539 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1618
Study 29649539 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1618
Study 29649853 — intervention group
Group type: EXPERIMENTAL
Intervention: p.N215S males
Number of subjects: 125
Study 29649853 — intervention group
Group type: EXPERIMENTAL
Intervention: p.N215S females
Number of subjects: 125
Study 29649853 — intervention group
Group type: EXPERIMENTAL
Intervention: p.N215S patients
Number of subjects: 125
Study 29649853 — intervention group
Group type: COMPARATOR
Intervention: classic Fabry patients
Number of subjects: 125
Study 29649885 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine 2.5 mg/d
Number of subjects: 33
Study 29649885 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg/d
Number of subjects: 33
Study 29649885 — intervention group
Group type: COMPARATOR
Intervention: Previous antihypertensive medications
Number of subjects: 33
Study 29649885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 33
Study 29649953 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy
Number of subjects: 206
Study 29649953 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 206
Study 29649953 — intervention group
Group type: EXPERIMENTAL
Intervention: Years with HIV/AIDS
Number of subjects: 206
Study 29649998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Conduction Studies (NCS)
Number of subjects: 115
Study 29649998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 115
Study 29650001 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic investigation with continuous cardiovascular monitoring
Number of subjects: 300
Study 29650056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic wrapping of the GDA stump using the pedicled falciform ligament
Number of subjects: 400
Study 29650056 — intervention group
Group type: COMPARATOR
Intervention: No wrap
Number of subjects: 400
Study 29650119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline testing (1 mg/kg/5 min)
Number of subjects: 191
Study 29650119 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study and substrate mapping or ablation
Number of subjects: 191
Study 29650119 — intervention group
Group type: EXPERIMENTAL
Intervention: Substrate ablation
Number of subjects: 191
Study 29650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat (100 mg to 1600 mg twice daily)
Number of subjects: 64
Study 29650362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat (800 mg twice daily)
Number of subjects: 64
Study 29650505 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal follow-up on day 3
Number of subjects: 4284
Study 29650505 — intervention group
Group type: COMPARATOR
Intervention: Conditional follow-up of nonsevere unclassified fever
Number of subjects: 4284
Study 29650555 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT patients with LONIPCs
Number of subjects: 198
Study 29650555 — intervention group
Group type: COMPARATOR
Intervention: History of chest irradiation prior to HSCT
Number of subjects: 198
Study 29650555 — intervention group
Group type: COMPARATOR
Intervention: History of pneumonia within 100 days post-HSCT
Number of subjects: 198
Study 29650555 — intervention group
Group type: COMPARATOR
Intervention: Low mean forced expiratory flow at 25-75% of forced vital capacity at day 100
Number of subjects: 198
Study 29650555 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival after diagnosis of LONIPCs
Number of subjects: 198
Study 29650558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 200
Study 29650558 — intervention group
Group type: COMPARATOR
Intervention: Control (chest radiograph)
Number of subjects: 200
Study 29650710 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of choline
Number of subjects: 6949
Study 29650710 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of choline
Number of subjects: 6949
Study 29650710 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of betaine
Number of subjects: 6949
Study 29650710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled hazard ratio for plasma concentrations of choline
Number of subjects: 6949
Study 29650773 — intervention group
Group type: EXPERIMENTAL
Intervention: CB1R antagonism
Number of subjects: 0
Study 29650773 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29651580 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization with glass and resin microspheres (32 patients with glass microspheres and 2 with resin microspheres)
Number of subjects: 34
Study 29651580 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization
Number of subjects: 34
Study 29651598 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) performed as standard procedure
Number of subjects: 15
Study 29651598 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) performed on indication
Number of subjects: 15